Skip to main content
Premium Trial:

Request an Annual Quote

New Molecular Dx Player Helixis Raises $10M in Series A Funding

Helixis, a newly formed molecular diagnostics firm based in Carlsbad, Calif., announced this week that it has raised $10 million in a Series A round of funding.
 
The firm was co-founded by Alex Dickinson, a former CEO of Luxtera who serves as Helixis’ CEO; David Baltimore, president emeritus and Robert Andrews Millikan professor of biology at the California Institute of Technology; and Axel Scherer, professor of electrical engineering, applied physics and physics at Caltech.
 
Helixis’ intellectual property portfolio is exclusively licensed from Caltech and comprises more than 40 patents and patent filings.
 
“We’ve developed a new generation of molecular diagnostic technology that radically reduces cost, size, and power requirements without compromising efficacy,” Dickinson said in a statement.
 
The firm did not provide specifics on its technology or how it offers these advantages over current molecular diagnostic technologies.
 
The funding was led by venture capitalists Jim Blair of Domain Associates and Sharon Stevenson of Okapi Venture Capital.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.